 PLANO, Texas, Dec. 01, 2020 GLOBE NEWSWIRE -- Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata or the Company, a clinical-stage biopharmaceutical company, today announced the launch of a proposed underwritten public offering by the Company of 2,000,000 shares of its Class A common stock pursuant to an existing shelf registration statement. Reata intends to grant the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions as the shares offered in the public offering. 